FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310497522> ?p ?o ?g. }

• W4310497522 endingPage "e005082" @default.
• W4310497522 startingPage "e005082" @default.
• W4310497522 abstract "Non-melanoma skin cancer (NMSC) includes a wide range of cutaneous tumors, the most frequent of which are basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (CSCC). Although NMSC is usually cured by surgical resection, in rare cases it can progress to locally advanced and metastatic disease. Risk factors for advanced disease include comorbidities, neglect, and immunosuppression. Advanced NMSC may require systemic treatment if surgery and radiation are not feasible. Chemotherapy, epidermal growth factor receptor (EGFR) inhibitors in CSCC, and hedgehog inhibitors in BCC have been used but are generally of limited benefit, with responses often short-lived and toxicity issues. Given the high mutational burden of NMSC, the use of immunotherapy has been investigated and two anti-PD-1 antibodies, cemiplimab and pembrolizumab, are approved for the treatment of advanced CSCC not curable by surgery or radiation. Both have shown durable responses with good tolerability in patients in phase II trials and anti-PD-1 therapy is now the standard of care for locally advanced and metastatic CSCC. PD-1 blockade is also approved as second-line therapy in advanced BCC, with frequent and durable responses after failure on hedgehog inhibitor therapy. PD-1 checkpoint inhibition is being assessed for NMSC in combination with other modalities, including oncolytic viruses and EGFR inhibitors. Adjuvant and neoadjuvant use of cemiplimab and pembrolizumab is also being investigated with several ongoing trials. Further clinical trials of immunotherapy must be prioritized in NMSC for further improvement in outcomes." @default.
• W4310497522 created "2022-12-11" @default.
• W4310497522 creator A5008736570 @default.
• W4310497522 creator A5034365278 @default.
• W4310497522 date "2022-12-01" @default.
• W4310497522 modified "2023-10-14" @default.
• W4310497522 title "Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma" @default.
• W4310497522 cites W1594237846 @default.
• W4310497522 cites W2093518411 @default.
• W4310497522 cites W2099120699 @default.
• W4310497522 cites W2101616608 @default.
• W4310497522 cites W2122406360 @default.
• W4310497522 cites W2146086092 @default.
• W4310497522 cites W2170144295 @default.
• W4310497522 cites W2316377680 @default.
• W4310497522 cites W2340861895 @default.
• W4310497522 cites W2776267727 @default.
• W4310497522 cites W2790292643 @default.
• W4310497522 cites W2805968856 @default.
• W4310497522 cites W2852818958 @default.
• W4310497522 cites W2888041146 @default.
• W4310497522 cites W2888104081 @default.
• W4310497522 cites W2892341912 @default.
• W4310497522 cites W2940153447 @default.
• W4310497522 cites W2947644219 @default.
• W4310497522 cites W2947891745 @default.
• W4310497522 cites W2947947780 @default.
• W4310497522 cites W2990860528 @default.
• W4310497522 cites W2995733451 @default.
• W4310497522 cites W2998138744 @default.
• W4310497522 cites W2998989384 @default.
• W4310497522 cites W3002973089 @default.
• W4310497522 cites W3031691917 @default.
• W4310497522 cites W3038010268 @default.
• W4310497522 cites W3046607405 @default.
• W4310497522 cites W3087940107 @default.
• W4310497522 cites W3123701916 @default.
• W4310497522 cites W3124665104 @default.
• W4310497522 cites W3160231856 @default.
• W4310497522 cites W3174756745 @default.
• W4310497522 cites W3184066167 @default.
• W4310497522 cites W3193495508 @default.
• W4310497522 cites W3200183519 @default.
• W4310497522 cites W3201959358 @default.
• W4310497522 cites W3202380124 @default.
• W4310497522 cites W3202485719 @default.
• W4310497522 cites W3204114712 @default.
• W4310497522 cites W3204191778 @default.
• W4310497522 cites W3216735902 @default.
• W4310497522 cites W3217278320 @default.
• W4310497522 cites W4200617909 @default.
• W4310497522 cites W4206124656 @default.
• W4310497522 doi "https://doi.org/10.1136/jitc-2022-005082" @default.
• W4310497522 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36455990" @default.
• W4310497522 hasPublicationYear "2022" @default.
• W4310497522 type Work @default.
• W4310497522 citedByCount "6" @default.
• W4310497522 countsByYear W43104975222023 @default.
• W4310497522 crossrefType "journal-article" @default.
• W4310497522 hasAuthorship W4310497522A5008736570 @default.
• W4310497522 hasAuthorship W4310497522A5034365278 @default.
• W4310497522 hasBestOaLocation W43104975221 @default.
• W4310497522 hasConcept C121608353 @default.
• W4310497522 hasConcept C126322002 @default.
• W4310497522 hasConcept C143998085 @default.
• W4310497522 hasConcept C16005928 @default.
• W4310497522 hasConcept C2777701055 @default.
• W4310497522 hasConcept C2777789703 @default.
• W4310497522 hasConcept C2778804307 @default.
• W4310497522 hasConcept C2780057760 @default.
• W4310497522 hasConcept C3019992690 @default.
• W4310497522 hasConcept C71924100 @default.
• W4310497522 hasConceptScore W4310497522C121608353 @default.
• W4310497522 hasConceptScore W4310497522C126322002 @default.
• W4310497522 hasConceptScore W4310497522C143998085 @default.
• W4310497522 hasConceptScore W4310497522C16005928 @default.
• W4310497522 hasConceptScore W4310497522C2777701055 @default.
• W4310497522 hasConceptScore W4310497522C2777789703 @default.
• W4310497522 hasConceptScore W4310497522C2778804307 @default.
• W4310497522 hasConceptScore W4310497522C2780057760 @default.
• W4310497522 hasConceptScore W4310497522C3019992690 @default.
• W4310497522 hasConceptScore W4310497522C71924100 @default.
• W4310497522 hasFunder F4320311600 @default.
• W4310497522 hasFunder F4320333587 @default.
• W4310497522 hasIssue "12" @default.
• W4310497522 hasLocation W43104975221 @default.
• W4310497522 hasLocation W43104975222 @default.
• W4310497522 hasLocation W43104975223 @default.
• W4310497522 hasOpenAccess W4310497522 @default.
• W4310497522 hasPrimaryLocation W43104975221 @default.
• W4310497522 hasRelatedWork W139793809 @default.
• W4310497522 hasRelatedWork W1636503868 @default.
• W4310497522 hasRelatedWork W1994913176 @default.
• W4310497522 hasRelatedWork W2036533781 @default.
• W4310497522 hasRelatedWork W2078269557 @default.
• W4310497522 hasRelatedWork W3082808696 @default.
• W4310497522 hasRelatedWork W3109198610 @default.
• W4310497522 hasRelatedWork W3215044659 @default.

• next